Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-targeted therapies for fibrotic diseases. The company's lead asset, bexotegrast (PLN-74809), is in Phase 2b trials for idiopathic pulmonary fibrosis (IPF) with potential expansion into primary sclerosing cholangitis (PSC). With $100M market cap, negative cash flow of $200M annually, and 13.9x current ratio, PLRX represents a binary clinical-stage bet with approximately 2-3 years of cash runway based on current burn rate.
PLRX operates a classic biotech R&D model with no current revenue. Value creation depends on successful clinical trial readouts, regulatory approvals, and eventual commercialization or partnership deals. The company targets integrin pathways (specifically αvβ6 and αvβ1) implicated in tissue fibrosis across multiple organs. Monetization pathways include: (1) direct commercialization post-approval requiring significant capital raise, (2) licensing deals with major pharma partners providing upfront payments and royalties, or (3) acquisition by larger biopharma. The IPF market has established precedents with Boehringer's Ofev and Roche's Esbriet generating $2B+ combined annual sales, suggesting commercial viability if clinical efficacy is demonstrated.
Phase 2b bexotegrast clinical trial data readouts in IPF (primary endpoint: forced vital capacity decline)
FDA regulatory pathway clarity and potential breakthrough therapy designation decisions
Partnership or licensing deal announcements with major pharmaceutical companies providing non-dilutive funding
Cash runway updates and equity financing announcements (dilution risk given negative $200M annual burn)
Competitive clinical data from Boehringer, Roche, or other fibrosis-focused biotechs affecting market positioning
Clinical trial failure risk - Phase 2b/3 trials have 30-40% historical success rates in fibrotic diseases; negative efficacy or safety data would eliminate near-term value
Regulatory pathway uncertainty - FDA approval standards for IPF therapies require demonstrating meaningful FVC improvement and survival benefits over 12-18 month trials
Competitive landscape evolution - established therapies (Ofev, Esbriet) set high efficacy bars; emerging competitors targeting similar integrin pathways could commoditize mechanism
Capital markets access risk - need for $300-500M additional funding to reach commercialization creates dependence on favorable biotech financing windows
Boehringer Ingelheim and Roche dominate IPF market with established sales infrastructure, physician relationships, and real-world efficacy data
Multiple clinical-stage competitors pursuing integrin-targeted and alternative fibrosis mechanisms (Galecto, Blade Therapeutics, Morphic Therapeutic) create crowded pipeline
Large pharma internal programs could leapfrog with superior efficacy, safety, or dosing convenience (oral vs. inhaled formulations)
Cash runway risk - $200M annual burn with $100M market cap implies imminent need for dilutive financing within 12-18 months absent partnership
Equity dilution risk - at current $0.40 price-to-book, future raises would significantly dilute existing shareholders; 50-100% dilution likely before commercialization
Going concern risk - if Phase 2b data disappoints or financing markets close, company may lack resources to complete development programs
low - Clinical-stage biotech operations are largely insulated from GDP fluctuations. R&D spending, clinical trial execution, and regulatory timelines proceed independently of economic cycles. However, financing conditions (ability to raise capital) and M&A activity (acquisition probability) are cyclically sensitive. IPF patient diagnosis and treatment rates show minimal economic sensitivity as the disease affects older populations with Medicare coverage.
High sensitivity through multiple channels: (1) Valuation impact - biotech stocks trade on discounted future cash flows, making them highly sensitive to risk-free rate changes; rising rates compress NPV of distant approval/revenue scenarios. (2) Financing costs - while current debt is minimal (0.30 D/E), future capital raises become more expensive in high-rate environments. (3) Risk appetite - higher rates reduce investor appetite for speculative, cash-burning growth stories, widening biotech risk premiums. The 58% one-year decline correlates with 2024-2025 rate environment.
Minimal direct credit exposure given pre-revenue status and strong 13.9x current ratio. However, credit market conditions significantly affect: (1) ability to access capital markets for future equity raises needed to fund operations, (2) venture debt availability as non-dilutive financing alternative, and (3) acquisition probability as strategic buyers' financing costs impact M&A appetite. Tightening credit conditions increase dilution risk from equity raises at depressed valuations.
growth - Attracts speculative biotech investors seeking asymmetric risk/reward from binary clinical catalysts. Typical holders include specialized healthcare hedge funds, biotech-focused venture investors, and retail traders betting on positive trial readouts. Not suitable for value or income investors given negative earnings, no dividends, and high cash burn. The 58% one-year decline has likely concentrated ownership among distressed/contrarian buyers expecting clinical success to drive multi-bagger returns.
high - Clinical-stage biotechs exhibit extreme volatility around data catalysts, with 30-50% single-day moves common on trial results. Beta likely exceeds 2.0x relative to broader biotech indices. The -20% three-month and -58% one-year returns reflect both sector-wide biotech weakness and company-specific clinical/financing concerns. Implied volatility typically spikes 50-100% ahead of major data readouts.